WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60

Login

Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :
Dr. Muhammad Baqir MR Fakhrildin
Download Article: Click Here

Search

Track Your Article

Abstract

STUDY OF TUMOR MARKERS IN BREAST AND OVARIAN CANCER PATIENTS

Padmaja S. Giram*, Prasad Neerti, Omprakash G. Bhusnure, Arun V. Dawale 

ABSTRACT

Screening for breast and ovarian cancers are required due to the late stage at diagnosis of cancer and poor survival. Serum CA125 and CA15-3 were important cancer detecting agents in patients with ovarian and breast cancers, respectively. CA15.3 and CA125, by itself, has been shown to be a usefully prognostic marker collectively with routine histopathological markers like tumor size, grade and stage in the management of breast cancer. The study (Breast cancer) was carried out on 25 subjects comparing 12 normal healthy volunteers and 13 patients of breast cancer with the range of 30-65years. The mean age of all breast cancers was 47.75 ± 3.19 years with minimum and maximum ages being 30 and 65 years respectively. The CA 15.3 values in serum ranged from 49.25-730.8 U/ml in the breast cancer group and 5.89-20.10 U/ml in control group. The study (Ovarian cancer) was carried out on 32 subjects comparing 13 normal healthy volunteers and 19 Patients of ovarian cancer with the range of 30-60years. The mean age of all ovarian cancers was 45 ± 2.0604 years with minimum and maximum ages being 30 and 60 years respectively. The CA 125 values in serum ranged from 40.6 – 59.028 U/ml in the ovarian cancer group and 5.89-20.15 U/ml in control group. The study demonstrated a correlation between the stage of breast cancer and ovarian cancer with CA 15.3 and CA125 positivity rate respectively. The higher the cancer stage, more likely that CA15.3 and CA125 will be elevated. The incidence of CA15.3 and CA125 in early stage disease indicates that it can be used in screening and diagnosis. It was also discovered that CA15.3 and CA125 were more sensitive in detecting the disease earlier before the clinical evidence of the disease. The treatment (Radiation and chemotherapy) results were more reducing level of CA15.3 in breast cancer and CA125 in ovarian cancer with the response to the treatment. A raised CA15.3 and CA125 may prompt the physician to exclude the presence of metastatic disease. Hence an initial estimation of CA15.3 and CA125 should be considered for the routine investigation in the management of patients with breast cancer and ovarian cancer respectively. Statistical analysis was performed by using SPSS 15.0 statistical software and Graph Pad Prism 5 for windows. The Unpaired t-test was used to compare the serum CA 15.3 and CA 125 concentration, the age, histopathological result and menopausal status.

Keywords: Breast and ovarian cancer, Tumer Marker, Malignancy, Screening and Diagnosis


[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More